US 11,926,663 B2
IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases
Greg Del Val, Rolle (CH); and Eduardo Schiffrin, Crissier (CH)
Assigned to AB2 BIO SA, Lausanne (CH)
Filed by AB2 BIO SA, Lausanne (CH)
Filed on Mar. 8, 2021, as Appl. No. 17/195,518.
Application 17/195,518 is a continuation of application No. 16/883,906, filed on May 26, 2020.
Application 16/883,906 is a continuation of application No. 15/555,446, granted, now 10,882,905, issued on Jan. 5, 2021, previously published as PCT/EP2016/054524, filed on Mar. 3, 2016.
Claims priority of application No. 15157742 (EP), filed on Mar. 5, 2015; application No. 15158781 (EP), filed on Mar. 12, 2015; and application No. 15186626 (EP), filed on Sep. 24, 2015.
Prior Publication US 2021/0188968 A1, Jun. 24, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/17 (2006.01); C07K 16/24 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/244 (2013.01) [A61K 38/1709 (2013.01); G01N 33/6869 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/30 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); G01N 2333/54 (2013.01)] 28 Claims
 
1. A method for the treatment of a pediatric autoinflammatory disease or condition and/or symptoms associated with said disease or condition in a subject, said method comprising administering to said subject an IL-18 inhibitor, wherein the IL-18 inhibitor is an IL-18 binding protein (IL-18BP) or an active fragment thereof, wherein the IL-18BP or the active fragment thereof comprises N-terminal and/or C-terminal deletion variants of IL-18BP, which are present in an amount of less than 30%.